<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588002</url>
  </required_header>
  <id_info>
    <org_study_id>NP28103</org_study_id>
    <nct_id>NCT01588002</nct_id>
  </id_info>
  <brief_title>A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers</brief_title>
  <official_title>A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This phase 1, randomized, open-label, multiple-dose, 2-sequence, 2-period crossover study&#xD;
      will evaluate potential drug-drug interaction between efavirenz and danoprevir with low-dose&#xD;
      ritonavir in healthy volunteers. In Period 1. subjects will be randomized to receive multiple&#xD;
      oral doses of either danoprevir with ritonavir or efavirenz for 14 days. In Period 2, all&#xD;
      subjects will receive multiple oral doses of the combination danoprevir with ritonavir and&#xD;
      efavirenz for 14 days. Anticipated time on study treatment is 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Cmax</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Days 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of efavirenz, danoprevir and ritonavir in coadministration: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Days 14 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>B efavirenz</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>A danoprevir+ritonavir</arm_group_label>
    <arm_group_label>C combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female non-smoking subjects, 18 to 55 years of age&#xD;
&#xD;
          -  Healthy status will be defined by absence of evidence of any active or chronic disease&#xD;
             following a detailed medical and surgical history and a complete physical examination&#xD;
&#xD;
          -  Medical history without major, recent or ongoing pathology&#xD;
&#xD;
          -  Weight &gt;/= 50.0 kg&#xD;
&#xD;
          -  Body mass index (BMI) 18.0 - 32.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women or males with female partners who are pregnant or&#xD;
             lactating&#xD;
&#xD;
          -  History of any clinically significant medical condition which may impact the safety of&#xD;
             the participant&#xD;
&#xD;
          -  Positive results for drugs of abuse at screening or prior to admission to the clinical&#xD;
             site during any study period&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C or HIV infection&#xD;
&#xD;
          -  Current smokers or subjects who have discontinued smoking less than 6 months prior to&#xD;
             first dose of study medication&#xD;
&#xD;
          -  Use of hormonal contraceptives (e.g. birth control pill, patches, or injectable,&#xD;
             implantable devices) within 30 days before the first dose of study medication&#xD;
&#xD;
          -  Use of investigational drug or device within 30 days of the first dose of study&#xD;
             medication (6 months for biologic therapies) or 5 half-lives of the investigational&#xD;
             drug, whichever is longer&#xD;
&#xD;
          -  History of drug-related allergic reaction&#xD;
&#xD;
          -  History (within 3 months of screening) of alcohol consumption exceeding 2 standard&#xD;
             drinks per day on average; alcohol consumption will be prohibited 72 hours prior to&#xD;
             entry in the clinical site center and throughout the entire study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

